- Home
- CRVS vs EPSN Comparison
CRVS vs EPSN Comparison
Compare CRVS & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- EPSN
- Stock Information
- Founded
- CRVS 2014
- EPSN 2005
- Country
- CRVS United States
- EPSN Canada
- Employees
- CRVS N/A
- EPSN N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- EPSN Oil & Gas Production
- Sector
- CRVS Health Care
- EPSN Energy
- Exchange
- CRVS Nasdaq
- EPSN Nasdaq
- Market Cap
- CRVS 395.9M
- EPSN 121.5M
- IPO Year
- CRVS 2016
- EPSN N/A
- Fundamental
- Price
- CRVS $7.21
- EPSN $6.01
- Analyst Decision
- CRVS Buy
- EPSN Strong Buy
- Analyst Count
- CRVS 4
- EPSN 1
- Target Price
- CRVS $10.83
- EPSN $7.00
- AVG Volume (30 Days)
- CRVS 519.3K
- EPSN 46.7K
- Earning Date
- CRVS 11-05-2024
- EPSN 11-07-2024
- Dividend Yield
- CRVS N/A
- EPSN 4.28%
- EPS Growth
- CRVS N/A
- EPSN N/A
- EPS
- CRVS N/A
- EPSN 0.24
- Revenue
- CRVS N/A
- EPSN $30,167,901.00
- Revenue This Year
- CRVS N/A
- EPSN N/A
- Revenue Next Year
- CRVS N/A
- EPSN N/A
- P/E Ratio
- CRVS N/A
- EPSN $24.25
- Revenue Growth
- CRVS N/A
- EPSN N/A
- 52 Week Low
- CRVS $1.05
- EPSN $4.70
- 52 Week High
- CRVS $7.54
- EPSN $6.20
- Technical
- Relative Strength Index (RSI)
- CRVS 74.25
- EPSN 58.37
- Support Level
- CRVS $6.30
- EPSN $5.44
- Resistance Level
- CRVS $6.98
- EPSN $6.19
- Average True Range (ATR)
- CRVS 0.48
- EPSN 0.25
- MACD
- CRVS 0.13
- EPSN -0.01
- Stochastic Oscillator
- CRVS 87.96
- EPSN 75.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.